Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028
As per Triton’s
report, the Asia-Pacific Alzheimer’s disease therapeutics and diagnostics
market is estimated to develop with a CAGR of 7.25% over the forecasting period 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries assessed in this region include:
•
South Korea
•
ASEAN Countries
•
India
•
China
•
Japan
•
Australia & New Zealand
•
Rest of Asia-Pacific
The market in this
region is primarily driven by the ongoing population growth in developing
nations like India, China, and Japan, which also raises the overall geriatric
population. Individuals in the age group of 65 years and above are more vulnerable
to neurological diseases like Alzheimer’s, which is expected to bolster the
demand for AD therapeutics and diagnostics in the country.
As of 2019, there were 35.524
million individuals in Japan aged over 65 years, and this number is expected to
rise to 37.278 million individuals by 2030, according to the World Aging 2019 report.
The elderly are more likely to be affected by Alzheimer’s and other
neurological diseases. The considered market is thus anticipated to progress in
the near future as a result of this increased geriatric population.
The UN Population Fund’s
2017 report has estimated that, by 2030, nearly 1.7 million senior citizens in
India would be affected by dementia. The growth in the economy has led to
significant advancements in the Indian healthcare sector. Further, the growing
prevalence of Alzheimer’s disease across the nation has increased the need for
new medical technological developments for the early diagnosis and treatment of
dementia and cognitive impairment. This is expected to foster the Alzheimer’s disease therapeutics
and diagnostics market’s growth in the near future.
The original product manufactured
by a pharmaceutical company is known as branded medicine. When a company
produces a new medication, it must go through stringent testing and pass the evaluations
to ensure that it is effective for treatment and safe for use. Pharmaceutical
companies are granted exclusive manufacturing and distribution rights of these
branded medicines as they make significant investments in the development of such
medications.
The
report assesses the market based on therapeutics and diagnostics. Here,
the therapeutics segment comprises drug type, disease stage, and generic &
branded. Generic & branded is further divided into generic and branded.
The
eminent companies in the Alzheimer’s disease therapeutics and diagnostics
market include Biogen Inc, Amarantus Bioscience Holdings Inc, Teva
Pharmaceutical Industries Ltd, Baxter International Inc, Cognoptix Inc,
Novartis AG, GE Healthcare, Merck and Co, and Pfizer Inc.
Eisai Co Ltd is a leading
company that manufactures, distributes, and markets pharmaceuticals, with a
strong focus on prescription drugs. It has 15 centers for clinical research,
R&D, and drug discovery. Oncology and Neurology are the primary therapeutic
areas of focus for the company. Its product, Aricept, is an oral donepezil medication
aimed to treat dementia symptoms caused by Alzheimer’s disease (AD). Founded in
1941, Eisai Co Ltd is headquartered in Koishikawa Bunkyo-Ku, Japan.
Key deliverables of the report:
·
Market
CAGR during the forecasting years 2022-2028
·
Detailed
data highlighting key insights, industry components, and market strategies
·
Comprehensive
information and estimation of the Alzheimer’s disease therapeutics and
diagnostics market revenue growth in Asia-Pacific and its influence on the
parent market
·
In-depth
study of forthcoming trends in consumer behavioral patterns
·
A
meticulous analysis of the competitive landscape, vendor scorecard, and
Porter’s Five Forces Model
·
A
wide-ranging study of factors that will challenge the Asia-Pacific Alzheimer’s
disease therapeutics and diagnostics market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
Market by Type, End-user, and ..
VIEW REPORT1. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – COUNTRY OUTLOOK
5.1. CHINA
5.2. JAPAN
5.3. INDIA
5.4. SOUTH
KOREA
5.5. ASEAN
COUNTRIES
5.6. AUSTRALIA
AND NEW ZEALAND
5.7. REST
OF ASIA-PACIFIC
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK,
2022-2028 (IN $ MILLION)
TABLE 2: MARKET
ATTRACTIVENESS MATRIX
TABLE 3: VENDOR
SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS,
2022-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028 (IN $
MILLION)
TABLE 8: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2022-2028
(IN $ MILLION)
TABLE 9: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS,
2022-2028 (IN $ MILLION)
TABLE 10:
ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT
ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021
& 2028 (IN %)
FIGURE 6: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 & 2028 (IN %)
FIGURE 7: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 8: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2028 (IN $
MILLION)
FIGURE 9: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021 & 2028 (IN
%)
FIGURE 10: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2022-2028
(IN $ MILLION)
FIGURE 11: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO
MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2028 (IN $
MILLION)
FIGURE 13: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, 2021 &
2028 (IN %)
FIGURE 14: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021
& 2028 (IN %)
FIGURE 17: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2028 (IN
$ MILLION)
FIGURE 18: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2028
(IN $ MILLION)
FIGURE 20: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING,
2022-2028 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2028 (IN $
MILLION)
FIGURE 22: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC
ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2028 (IN $
MILLION)
FIGURE 24: ASIA-PACIFIC
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
& 2028 (IN %)
FIGURE 25: CHINA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $
MILLION)
FIGURE 26: JAPAN ALZHEIMER’S
DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $ MILLION)
FIGURE 27: INDIA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $
MILLION)
FIGURE 28: SOUTH KOREA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028 (IN $
MILLION)
FIGURE 29: ASEAN
COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028
(IN $ MILLION)
FIGURE 30: AUSTRALIA
& NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET,
2022-2028 (IN $ MILLION)
FIGURE 31: REST OF
ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2022-2028
(IN $ MILLION)